Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study F. Barata, H. Queiroga, E. Teixeira, T. Almodovar, M. Soares, B. Parente, J.C. Mellidez, P. Alves, A. Antunes

Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine F. Froes, A. Timóteo, B. Almeida, J.F. Raposo, J. Oliveira, M. Carrageta, S. Duque, A. Morais

Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters F. Estevinho, M. Felizardo, G. Fernandes, A. Figueiredo, J.A. Lopes